Drug intelligence / Profile preview

CBM-951

Development stage: Preclinical
Lead developer: Cellion BioMed
Modality: Small Molecules

Overview

CBM-951 is a preclinical small molecule inhibitor of the KCa3.1 channel (Intermediate conductance calcium-activated potassium channel protein 4), developed by Cellion BioMed. Part of the CBM-Nx/Fx series, it is being investigated for the treatment of autoimmune and inflammatory conditions, specifically Rheumatoid Arthritis and Multiple Sclerosis. The drug's mechanism of action involves the inhibition or modulation of KCa3.1, which leads to increased local concentrations of adenosine and cyclic adenosine monophosphate (cAMP). This biochemical shift results in anti-fibrotic, anti-inflammatory, and antioxidant effects. Cellion BioMed has conducted development in partnership with DtaCRO and Preclina.

Targets

KCNN4 (Intermediate conductance calcium-activated potassium channel protein 4)

Beyond the preview

Go deeper on CBM-951.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBM-951.

Explore the full profile